Author: Emma Yasinski

Emma Yasinski

I am a freelance science and medical journalist, fascinated by how the scientific process leads to incredible discoveries, but also can lead to publication bias leaning toward positive findings and minimizing negatives. With a bachelor’s degree in neuroscience from Lafayette College and a Master’s in Science and Medical Journalism from Boston University, I’ve written about clinical trial transparency, organ donation, and basic molecular biology for publications like The Scientist, The Atlantic,, Kaiser Health News, and more. At MedShadow, I research and write about the sometimes unexpected ways that medicines can affect us, and what we can do if and when it does.

The Food and Drug Administration (FDA) approved Tyrvaya, a new nasal spray designed to treat dry eye disease, in October 2021. A major benefit of the new drug is that it won’t require patients to apply drops directly to their eyes, which is very hard for some to tolerate. Some eye drops on the market irritate eyes and can even cause a rebound effect, making symptoms worse overtime. Some might wonder about the frequency with which patients are directed to use Tyrvaya. Rather than drops that are used as-needed, the new drug is a nasal spray that you squirt into…

Read More